Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LILLY ZYPREXA SHARE OF NEW ANTIPSYCHOTIC SCRIPTS INCREASES TO 12.9% IN JUNE; EVISTA PRIORITY REVIEW STATUS COULD GIVE LILLY A LATE 1997 APPROVAL

Executive Summary

Lilly's anti-psychotic Zyprexa (olanzapine) has captured almost 13% of new prescriptions through June, the company reported July 23. Zyprexa sales reached $156 mil. for the second quarter, the product's third quarter on the market. The product is tracking to reach $500 mil. in sales during its first 12 months of availability. Its market share at the end of June was 12.9%, up from 6% in January.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030588

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel